Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.34 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174489 | 0.80 | POLB (0.34) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL22058870 | 0.80 | NPC1 (0.39) | RAB9AKDM4E | |
| SCHEMBL9711587 | 0.79 | POLB (0.33) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL620180 | 0.78 | TSHR (0.37) | RAB9APOLBNPSR1TSHRADORA3 | |
| SCHEMBL8698153 | 0.78 | TSHR (0.37) | RAB9APOLBNPSR1TSHRADORA3 | |
| SCHEMBL2703082 | 0.76 | MAPT (0.38) | RAB9ANPSR1TSHRPSMB1IDH1 | |
| SCHEMBL8677952 | 0.74 | NOTUM (0.48) | POLBTSHRKDM4E | |
| SCHEMBL27500883 | 0.74 | POLB (0.36) | POLBNPSR1TSHRADORA3PSMB1 | |
| SCHEMBL1505859 | 0.74 | BCHE (0.39) | POLBNPSR1TSHRPSMB1KDM4E | |
| SCHEMBL23732646 | 0.73 | PSMB1 (0.36) | PTGS1RAB9APOLBNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119789746-A | Solar cell and preparation method thereof | 北京曜能光电科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-118638097-A | Preparation of diaryl thiohydantoin Process for the preparation of ureide compounds | 阿拉贡药品公司 | 2024-09-13 | — | — | CN | claimed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | claimed |
| CN-111620849-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2023122842-A1 | METHOD FOR PREPARING APALUTAMIDE, SYNTHESIS INTERMEDIARIES, AND AMORPHOUS SOLID DISPERSION CONTAINING APALUTAMIDE | GADOR LIMITADA (CL) | 2023-07-06 | — | — | WO | claimed |
| CN-111620849-A | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-09-04 | — | — | CN | claimed |
| US-10723714-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | claimed |
| CN-107108553-B | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-04-28 | — | — | CN | claimed |
| US-20190284156-A1 | Processes For The Preparation Of A Diarylthiohydantoin Compound | ARAGON PHARMACEUTICALS INC (US) | 2019-09-19 | — | — | US | claimed |
| US-10316015-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | claimed |
| US-9688655-B2 | Process for the preparation of a diarylthiohydantoin compound | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | claimed |
| WO-2016100645-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| WO-2016100652-A2 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20160176844-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | claimed |
| US-20160176845-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | claimed |
| US-20160002298-A1 | AMATOXIN DERIVATIVES | HEIDELBERG PHARMA GMBH (DE) | 2016-01-07 | — | — | US | claimed |
| EP-2774624-A1 | Amatoxin derivatives | Heidelberg Pharma GmbH (DE) | 2014-09-10 | — | — | EP | claimed |
| US-7053213-B2 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2006-05-30 | — | — | US | claimed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | claimed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002298-A1 | AMATOXIN DERIVATIVES | C3AR1, TNFSF10, ANXA5 | ESR1 3588/4885HSP90AA1 2688/4885MMP3 2413/4885 |
| US-20160176845-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | BPHL, CYP4X1, KLK3 | ESR1 1106/4885HSP90AA1 2796/4885MMP3 3139/4885 |
| US-20160176844-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | BPHL, CYP4X1, KLK3 | ESR1 861/4885HSP90AA1 2589/4885MMP3 3282/4885 |
| US-10723714-B2 | Processes for the preparation of a diarylthiohydantoin compound | BPHL, CYP4X1, KLK3 | ESR1 861/4885HSP90AA1 2589/4885MMP3 3282/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | ESR1 2571/4885HSP90AA1 1238/4885MMP3 4671/4885 |
| US-20190284156-A1 | Processes For The Preparation Of A Diarylthiohydantoin Compound | BPHL, CYP4X1, KLK3 | ESR1 861/4885HSP90AA1 2589/4885MMP3 3282/4885 |
| US-10316015-B2 | Processes for the preparation of a diarylthiohydantoin compound | BPHL, CYP4X1, KLK3 | ESR1 861/4885HSP90AA1 2589/4885MMP3 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.